Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Jun;221(6):649-56; discussion 656-9.
doi: 10.1097/00000658-199506000-00004.

Characterization of growth hormone enhanced donor site healing in patients with large cutaneous burns

Affiliations
Clinical Trial

Characterization of growth hormone enhanced donor site healing in patients with large cutaneous burns

D N Herndon et al. Ann Surg. 1995 Jun.

Abstract

Background: Human growth hormone is an anabolic agent that attenuates injury-induced catabolism and stimulates protein synthesis. Recombinant human growth hormone (rhGH) administered therapeutically to patients with massive burns has been shown to increase the rate of skin graft donor site healing. It has been postulated that growth hormone affects wound healing and tissue repair by stimulating the production of insulin-like growth factor-1 (IGF-1) by the liver to increase circulating IGF-1 concentrations. The mechanism by which it improves wound healing, however, remains in question. The authors hypothesize that rhGH up-regulates IGF-1 receptors and IGF-1 levels both systemically and locally in the wound site to stimulate cell mitosis and increase synthesis of laminin, collagen types IV and VII, and cytokeratin. This hypothesis was tested in nine patients with burns covering > 40% of total body surface area.

Objective: The authors assessed the efficacy of rhGH in promoting several major building materials in the donor site of patients with massive burns.

Methods: Ten massively burned patients with full-thickness burns covering more than 40% of total body surface area were participants in a placebo-controlled prospective study to determine the efficacy of 0.2 mg/kg/day rhGH on donor site wound healing and to identify some of the major components involved in wound healing and its integrity.

Results: Donor sites in burn patients receiving rhGH showed an increased coverage by the basal lamina of 26% for placebo to 68% coverage of the dermal-epidermal junction. Insulin-like growth factor-1 receptors and laminin, types IV and VII collagen, and cytokeratin-14 all increased significantly. Healing times of the donor sites were significantly decreased compared with patients receiving placebo.

Conclusion: Results indicate that growth hormone or its secondary mediators may directly stimulate the cells of the epidermis and dermis during wound healing to produce the structural proteins and other components needed to rebuild the junctional structures.

PubMed Disclaimer

References

    1. J Pediatr Surg. 1992 Aug;27(8):1026-8 - PubMed
    1. Ann Surg. 1994 Jul;220(1):19-24 - PubMed
    1. Acta Chir Scand. 1988 Nov-Dec;154(11-12):623-6 - PubMed
    1. Ann Surg. 1989 Oct;210(4):513-24; discussion 524-5 - PubMed
    1. J Burn Care Rehabil. 1989 Nov-Dec;10(6):523-6 - PubMed

Publication types